Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
BCDA

BCDA - BioCardia Inc Stock Price, Fair Value and News

$1.97+0.13 (+7.07%)
Delayed
Max Portfolio Pct.
Check
Valuation
Check

Stock Quality:

GPSDBMFI
Max Portfolio Pct.
Check
Valuation
Check
GPSDBMFI

BCDA Price Action

Last 7 days

-5.3%

Last 30 days

-1.0%

Last 90 days

-22.4%

Trailing 12 Months

203.1%

BCDA RSI Chart

BCDA Valuation

Market Cap

9.0M

Price/Earnings (Trailing)

-1.17

Price/Sales (Trailing)

127.2

EV/EBITDA

1.08

Price/Free Cashflow

-1.24

BCDA Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

BCDA Fundamentals

BCDA Revenue

Revenue (TTM)

71.0K

Rev. Growth (Yr)

-100%

Rev. Growth (Qtr)

-100%

BCDA Earnings

Earnings (TTM)

-7.7M

Earnings Growth (Yr)

32.52%

Earnings Growth (Qtr)

-5.53%

BCDA Profitability

Operating Margin

100.00%

EBT Margin

7560.56%

Return on Equity

-280.49%

Return on Assets

-123.22%

Free Cashflow Yield

-80.93%

BCDA Investor Care

Buy Backs (1Y)

78.80%

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
2024468.0K428.0K71.0K0
20231.4M425.0K570.0K477.0K
20221.1M1.2M1.3M1.4M
2021153.0K195.0K982.0K1.0M
2020532.5K473.5K313.5K145.0K
2019642.0K489.0K599.0K710.5K
2018541.0K668.0K622.0K625.0K
2017535.0K503.0K516.0K479.0K
2016946.0K965.0K961.0K576.0K
2015465.0K485.0K510.0K904.0K
2014328.0K364.0K389.0K427.0K
201389.0K141.0K193.0K268.0K
201224.5K37.0K49.5K62.0K
201100012.0K
Get all data in R, Python etc through our Historical Stock Data APIs

About BioCardia Inc

BCDA
BioCardia, Inc., a clinical-stage regenerative medicine company, engages in development of cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases. Its lead therapeutic candidate is the CardiAMP, an autologous mononuclear cell therapy system for the treatment of heart failure and chronic myocardial ischemia; and allogeneic cell therapy for cardiac and pulmonary disease. The company is also developing allogeneic cells therapeutic platform, an investigational culture expanded bone marrow derived mesenchymal cell therapy, which is in Phase I/II trial for the treatment of ischemic heart failure. In addition, it offers the Helix biotherapeutic delivery system that delivers therapeutics into the heart muscle with a penetrating helical needle from within the heart; and Morph deflectable guides and sheaths. The company is based in Sunnyvale, California.
 CEO
 WEBSITEbiocardia.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES30

BioCardia Inc Frequently Asked Questions

What is the ticker symbol for BioCardia Inc? What does BCDA stand for in stocks?

BCDA is the stock ticker symbol of BioCardia Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of BioCardia Inc (BCDA)?

As of Fri Dec 20 2024, market cap of BioCardia Inc is 9.03 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of BCDA stock?

You can check BCDA's fair value in chart for subscribers.

Is BioCardia Inc a good stock to buy?

The fair value guage provides a quick view whether BCDA is over valued or under valued. Whether BioCardia Inc is cheap or expensive depends on the assumptions which impact BioCardia Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for BCDA.

What is BioCardia Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Dec 20 2024, BCDA's PE ratio (Price to Earnings) is -1.17 and Price to Sales (PS) ratio is 127.2. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. BCDA PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on BioCardia Inc's stock?

In the past 10 years, BioCardia Inc has provided -0.164 (multiply by 100 for percentage) rate of return.